Lung cancer is the leading cause of death from cancer in both men and women [1] . Despite advances in treatment, the 5-year overall survival rate is approximately 15.7% [2] . Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases [3] . In the last several decades adenocarcinoma has become the predominant type of NSCLC [4, 5] . Currently, the pathological stage is the most important system to predict survival in patients with NSCLC [6] and to define groups with similar treatment strategies [7] . However, additional prognostic markers are needed in order to refine prognostic profiles that can potentially select patients who will benefit most from established treatments and save others from toxicity of ineffective treatments. Moreover, the discovery of novel molecular alterations may help identify potential therapeutic targets that would be more efficient and less harmful than current treatments.
Introduction
Lung cancer is the leading cause of death from cancer in both men and women [1] . Despite advances in treatment, the 5-year overall survival rate is approximately 15.7% [2] . Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases [3] . In the last several decades adenocarcinoma has become the predominant type of NSCLC [4, 5] . Currently, the pathological stage is the most important system to predict survival in patients with NSCLC [6] and to define groups with similar treatment strategies [7] . However, additional prognostic markers are needed in order to refine prognostic profiles that can potentially select patients who will benefit most from established treatments and save others from toxicity of ineffective treatments. Moreover, the discovery of novel molecular alterations may help identify potential therapeutic targets that would be more efficient and less harmful than current treatments.
Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a 38-kD transcription factor that is normally expressed in adult thyroid and lung tissue [8] and is essential in lung development [9] [10] [11] . It is expressed in type II pneumocytes in the normal adult lung [8] adenocarcinomas [12] . Currently, testing for TTF-1 expression by immunohistochemistry is commonly used to confirm the pulmonary origin of a carcinoma [12, 13] . Several studies have evaluated the prognostic significance of TTF-1 expression in NSCLC [14] [15] [16] [17] [18] [19] [20] and lung adenocarcinoma specifically [13, [21] [22] [23] . Although studies reporting the prognostic significance of TTF-1 are conflicting, most have shown that TTF-1 is a favourable prognostic factor for survival in patients with lung adenocarcinoma [15] .
We recently have shown that the gene that encodes TTF-1, located on chromosome 14q13.3, is amplified in approximately 12% of lung adenocarcinomas [24] . Furthermore, amplification of the TTF-1 gene is the single most common focal genetic event assessed by high-resolution copy-number analysis of lung adenocarcinoma [24] . The [24] . Tissue hybridization, washing and colour detection were performed as described previously [28] [29] [30] 
Materials and methods

Patient characteristics
Immunohistochemical analysis for TTF-1 expression
Fig. 1 TTF1 amplification by fluorescence in situ hybridization (FISH). (A) FISH for NKX2-1 (TTF1, red) and a chromosome 14 reference probe (green) on a lung adenocarcinoma specimen with high-level amplification of the NKX2-1 probe. Nuclei are stained with DAPI (blue). The box shows a single nucleus. (B) FISH on lung adenocarcinoma tissue without amplification. The boxed area shows a representative nucleus. (C) FISH for NKX2-1 (red) and a chromosome 14 reference probe (green) on a lung adenocarcinoma specimen with polysomy. Nuclei are stained with DAPI (blue). The box shows a single nucleus. samples from TMAs or full-mount sections from paraffin blocks in cases with insufficient probe hybridization or lack of viable tumour on the TMA slide. A Biotin-14-dCTP labelled BAC clone RP11-1083E2 (conjugated to produce a red signal) was used for the NKX2-1 probe and a DigoxindUTP labelled BAC clone RP11-72J8 (conjugated to produce a green signal) was used for the reference probe
Results
Patient demographics and pathological characteristics
The clinicopathological characteristics of the patients with lung adenocarcinoma included in this study are summarized in Table 1 Table 3 . In contrast, there was no difference in overall survival between patients with or without TTF-1 gene amplification (median 39.5 versus 67.1 months, P ϭ 0.508, Fig. 3B ). 
Survival analysis
The median follow-up period was 87 months (range 4-110 months) among the 37 patients still alive. The overall survival time was significantly longer for patients with adenocarcinomas with high (median 72.4 months) or low TTF-1 expression (median 77.8 months), than for patients with adenocarcinomas with absent TTF-1 expression (median 30.5 months) (P ϭ 0.002, Fig. 3A). Overall survival did not differ significantly between patients with adenocarcinomas with low TTF-1 expression and patients with adenocarcinomas with high TTF-1 expression (P ϭ 0.995). A multivariate model confirmed that patients with absent TTF-1 expression have a significantly worse prognosis [Hazard Ratio (HR) ϭ 2.6, P ϭ 0.003)] compared to patients with high or low TTF-1 expression. The model was adjusted for tumour size, dominant subtype and gender as potential confounders due to their associations with TTF-1 expression in
Presence of TTF-1 amplification in patients with adenocarcinomas with TTF-1 expression
Within our cohort, we found a group of 64 patients with adenocarcinomas with TTF-1 expression and an assessable TTF-1 gene amplification status. We identified two categories based on the FISH amplification status of the TTF-1 gene: patients with adenocarcinomas with TTF-1 expression and TTF-1 gene amplification (4 patients, 6%), and patients with adenocarcinomas with TTF-1 expression with TTF-1 non-amplified (60 patients, 94%,
TTF-1 expression was semi-quantitatively assigned to one of three categories: (A) No expression (absent staining ϭ 0). (B) Low expression (weak staining intensity ϭ 1), (C) High expression (strong staining intensity ϭ 2).
Characteristic
